Cytyc, TriPath Automatic In 2000; OTC Index Up 7%, Well Ahead Of Nasdaq

Cytyc's ability to leverage a favorable reimbursement environment in the U.S. for automated Pap tests, a well-oiled marketing operation, and a key agreement with Roche Diagnostics helped drive the company's stock to a 105% gain in 2000. The issue closed the year at 62.25, up 32.03 for the 12 months.